Game On, page-4

agreed. things will start to get v interesting in the lead up to the end of june

and only 13 trading days left in may ... by the end of which (if not earlier!) RAP will conclude and will have recruited up to 1,500 patients for its smartcough-c study (see announcement dated 19 april 2017)

we know that as @ 19 april --->

"The company advises that it remains on-track to complete enrolment, release top- line results and submit its de novo submission to the FDA in the first half of CY2017."

you would think the RAP team has a draft FDA submission sitting ready to be finalised when US study results become available

and RAP have engaged Experien Group "... a firm of highly experienced Silicon Valley-based FDA consultants who have achieved a 99% approval rate for regulatory submissions." (see announcement dated 3 september 2015) to assist in the whole process.